Opendata, web and dolomites

ERGO SIGNED

Breaking down the wall between human health and environmental testing of endocrine disrupters: EndocRine Guideline Optimisation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ERGO" data sheet

The following table provides information about the project.

Coordinator
SYDDANSK UNIVERSITET 

Organization address
address: CAMPUSVEJ 55
city: ODENSE M
postcode: 5230
website: www.sdu.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 6˙998˙388 €
 EC max contribution 5˙992˙437 € (86%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYDDANSK UNIVERSITET DK (ODENSE M) coordinator 1˙273˙185.00
2    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 695˙665.00
3    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 610˙065.00
4    ECOLE NORMALE SUPERIEURE DE LYON FR (LYON) participant 534˙875.00
5    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 468˙040.00
6    HELMHOLTZ-ZENTRUM FUR UMWELTFORSCHUNG GMBH - UFZ DE (LEIPZIG) participant 450˙000.00
7    Masarykova univerzita CZ (BRNO STRED) participant 417˙875.00
8    AARHUS UNIVERSITET DK (AARHUS C) participant 411˙120.00
9    FORSCHUNGSVERBUND BERLIN EV DE (BERLIN) participant 410˙500.00
10    AquaTT UETP Ltd IE (DUBLIN) participant 324˙875.00
11    UMWELTBUNDESAMT DE (DESSAU-ROSSLAU) participant 206˙675.00
12    PETER MATTHIESSEN UK (LLANWRTYD WELLS) participant 104˙249.00
13    BASF SE DE (LUDWIGSHAFEN AM RHEIN) participant 85˙312.00
14    Dow AgroSciences LLC US (INDIANAPOLIS) participant 0.00
15    L'OREAL SA FR (PARIS) participant 0.00
16    PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY JP (YOKOHAMA) participant 0.00

Map

 Project objective

ERGO presents a new approach that will support a paradigm shift in the regulatory use of standardized test guidelines (TGs) by breaking the existing wall between mammalian and non-mammalian vertebrate testing and assessment of endocrine disrupting chemicals (EDCs). The highly conserved thyroid system will be used as the “proof of concept”, but also other conserved endocrine axes/systems such as the Retinoid X Receptor (RXR) and the Hypothalamus Pituitary Gonadal (HPG) axis can be adapted to the cross-vertebrate class approach. ERGO will investigate a battery of draft in vitro assays and evaluate thyroid-responsive biomarkers and endpoints (B/E) suitable for extrapolation of effects from fish and amphibian tests to humans and other mammals (and vice versa) and finally validate successful B/E for inclusion in existing in vivo or new in vitro OECD TGs. A cross-class adverse outcome pathway (AOP) network will provide the scientifically plausible and evidence-based foundation for the selection of B/E in lower vertebrate assays predictive of human health outcomes. In silico modeling and biotransformation data will support cross-vertebrate class effect extrapolation. Major outcomes of ERGO will be: 1) New thyroid-related B/E for inclusion in OECD TGs for improved identification of TDC. 2) An Integrated Approach to Testing and Assessment (IATA) of chemicals for TD based on a multi-class vertebrate AOP network connecting endocrine mechanisms in one vertebrate class to adverse outcomes in another class for safer regulation of EDCs. 3) A tool for TG end users, such as regulators and industry, to extrapolate thyroid effects between vertebrate classes. Implementation of the ERGO IATA strategy in regulations of EDC will make hazard and risk assessment faster, cheaper, simpler and safer and support industry in the development of EDC-free products beneficial for environmental and human safety.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ERGO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ERGO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DC-ren (2020)

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More